Search Results

You are looking at 101 - 110 of 117 items for :

  • Cushing���s disease x
  • Refine by Access: All content x
Clear All
Open access

L Ghataore, I Chakraborti, S J Aylwin, K-M Schulte, D Dworakowska, P Coskeran, and N F Taylor

Introduction Mitotane (o,p'-DDD) plays an important role in adjuvant therapy of adrenocortical carcinoma (ACC) and in advanced stage disease (1) . This application was first reported in 1959 by Bergenstal et al . (2) , but mitotane has only been

Open access

Pinaki Dutta, Bhuvanesh Mahendran, K Shrinivas Reddy, Jasmina Ahluwalia, Kim Vaiphei, Rakesh K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, Viral N Shah, Girish Parthan, and Anil Bhansali

) level <2 s.d . below age-specific normal range (13) . Patients who were on pharmacological therapy for acromegaly, unstable cardiovascular disease, uncontrolled hypertension or diabetes mellitus, pregnancy or lactation, previous history or active

Open access

Xi Wang and Qi Yu

– 157 . ( ) 27 Collins MT Singer FR Eugster E. McCune–Albright syndrome and the extraskeletal manifestations of fibrous dysplasia . Orphanet Journal of Rare Diseases 2012 7 ( Supplement 1 ) S4 . ( https

Open access

Anru Wang, Xueqin Yan, Cai Zhang, Caiqi Du, Wenjun Long, Di Zhan, and Xiaoping Luo

and daily physical activity, refer to clinical practice guidelines ( 12 , 13 ). Individuals who had specific medical diagnoses (e.g., hypothyroidism, Cushing’s syndrome or polycystic ovary syndrome) and/or current use of medications that may affect

Open access

M Jensterle, A Podbregar, K Goricar, N Gregoric, and A Janez

methods Subjects Thirty middle-aged obese men with FH (aged 46.5 ± 10.9 years, BMI 41.2 ± 8.4 kg/m 2 , mean ±  s.d. ) who had been previously poor responders to LSM, by means of WR and recovery of FH, were included in the study. They were eligible

Open access

Feifei Cheng, Noel Yat Hey Ng, Claudia Ha Ting Tam, Yuying Zhang, Cadmon King Poo Lim, Guozhi Jiang, Alex Chi Wai Ng, Tiffany Tse Ling Yau, Lai Ping Cheung, Aimin Xu, Juliana C N Chan, and Ronald C W Ma

, and subjects who were previously diagnosed with hypothyroidism, prolactinoma, non-classical adrenal hyperplasia and Cushing’s syndrome. Between January 2016 and December 2017, all PCOS controls were recalled to visit the Diabetes Mellitus & Endocrine

Open access

Krzysztof C Lewandowski, Justyna Płusajska, Wojciech Horzelski, Ewa Bieniek, and Andrzej Lewiński

ovaries) on condition that other causes of oligo-/anovulation or hyperandrogenism/hyperandrogenaemia (hyperprolactinaemia, Cushing’s syndrome, congenital adrenal hyperplasia, premature ovarian failure, hypothalamic/pituitary disease, etc.) have been ruled

Open access

Xiying Zeng, Yinxiang Huang, Mulin Zhang, Yun Chen, Jiawen Ye, Yan Han, Danyan Ma, Xin Zheng, Xiaohong Yan, and Changqin Liu

congenital adrenal hyperplasia, androgen-secreting tumors, and Cushing’s syndrome ( 1 , 26 ). The ethics committee of the First Affiliated Hospital of Xiamen Medical University approved the study protocol. Clinical and biochemical measurements All

Open access

Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Piet Kramer, Richard A Feelders, Patric J D Delhanty, and Wouter W de Herder

following: past or existent malignancies; endocrine disorders including diabetes mellitus, acromegaly, Cushing syndrome; metabolic syndrome; any active use of glucocorticoids; active inflammatory or infectious disease; past gastric surgery, kidney, or liver

Open access

Katarzyna Wyskida, Grzegorz Franik, Tomasz Wikarek, Aleksander Owczarek, Alham Delroba, Jerzy Chudek, Jerzy Sikora, and Magdalena Olszanecka-Glinianowicz

mass index (BMI) during the 3-month period before the study. Patients diagnosed with polycystic ovary syndrome (PCOS), Cushing’s syndrome, thyroid dysfunctions, androgen-secreting tumor, and enzyme deficiency (21-hydroxylase in particular), decreased